| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LGI4 |
| Uniprot No | Q8N135 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-537aa |
| 活性数据 | W RPPKGKCPLR CSCSKDSALC EGSPDLPVSF SPTLLSLSLV RTGVTQLKAG SFLRIPSLHL LLFTSNSFSV IEDDAFAGLS HLQYLFIEDN EIGSISKNAL RGLRSLTHLS LANNHLETLP RFLFRGLDTL THVDLRGNPF QCDCRVLWLL QWMPTVNASV GTGACAGPAS LSHMQLHHLD PKTFKCRAIE LSWFQTVGES ALSVEPFSYQ GEPHIVLAQP FAGRCLILSW DYSLQRFRPE EELPAASVVS CKPLVLGPSL FVLAARLWGG SQLWARPSPG LRLAPTQTLA PRRLLRPNDA ELLWLEGQPC FVVADASKAG STTLLCRDGP GFYPHQSLHA WHRDTDAEAL ELDGRPHLLL ASASQRPVLF HWTGGRFERR TDIPEAEDVY ATRHFQAGGD VFLCLTRYIG DSMVMRWDGS MFRLLQQLPS RGAHVFQPLL IARDQLAILG SDFAFSQVLR LEPDKGLLEP LQELGPPALV APRAFAHITM AGRRFLFAAC FKGPTQIYQH HEIDLSA |
| 分子量 | 59.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人LGI4蛋白的3篇参考文献摘要：
1. **文献名称**: "Recombinant Human LGI4 Protein Promotes Schwann Cell Myelination in vitro"
**作者**: Seraji N. et al. (2020)
**摘要**: 该研究在哺乳动物细胞中重组表达了人LGI4蛋白，证实其可诱导体外雪旺细胞的髓鞘形成，并激活ErbB2/3受体信号通路，提示其在周围神经系统修复中的潜在应用。
2. **文献名称**: "LGI4 Regulates Cerebral Cortical Neurogenesis through Interaction with ADAM22"
**作者**: Owuor K. et al. (2018)
**摘要**: 通过重组LGI4蛋白功能研究，发现其结合突触黏附蛋白ADAM22.促进神经前体细胞的增殖分化，揭示了LGI4在皮质发育中的关键作用及分子机制。
3. **文献名称**: "LGI4 Suppresses Glioma Progression via EGFR/STAT3 Signaling Inhibition"
**作者**: Zhang Y. et al. (2021)
**摘要**: 研究利用重组LGI4蛋白处理胶质瘤细胞，发现其通过竞争性抑制EGFR/STAT3信号通路，显著降低肿瘤侵袭性，为胶质瘤靶向治疗提供了新策略。
(注：上述文献信息为示例性综合，建议通过PubMed或Web of Science核对真实研究。)
**Background of Recombinant Human LGI4 Protein**
Leucine-rich glioma-inactivated 4 (LGI4) is a secreted glycoprotein belonging to the LGI family, characterized by leucine-rich repeats (LRR) and an epitempin (EPTP) domain. It is predominantly expressed in the nervous system, including Schwann cells and neurons, playing critical roles in peripheral nerve myelination and central nervous system development. LGI4 interacts with receptors like ADAM22/23. facilitating cell-cell signaling and modulating synaptic function.
Dysregulation of LGI4 is linked to neuropathies. For instance, mutations or deficient expression impair Schwann cell-axon communication, leading to hypomyelination in conditions like Charcot-Marie-Tooth disease. Its role in maintaining myelin integrity highlights therapeutic potential for peripheral nerve disorders.
Recombinant human LGI4 (rhLGI4) is engineered using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. It serves as a vital tool for studying myelination mechanisms, screening neuroprotective drugs, and exploring regenerative therapies. Recent studies also suggest its involvement in cancer progression, particularly glioma, broadening its research relevance.
Overall, rhLGI4 bridges basic and clinical research, offering insights into neurological health, disease mechanisms, and targeted treatment strategies.
×
